Onset of Pyoderma Gangrenosum in Patients on Biologic Therapies: A Systematic Review.
OBJECTIVE: To summarize clinical outcomes of paradoxical pyoderma gangrenosum (PG) onset in patients on biologic therapy. METHODS: The authors conducted MEDLINE and EMBASE searches using PRISMA guidelines to include 57 patients (23 reports). RESULTS: Of the included patients, 71.9% (n = 41/57) noted...
| Publicado en: | Advances in Skin & Wound Care Vol. 35; no. 8; pp. 454 - 461 |
|---|---|
| Autores principales: | , , , , |
| Formato: | research systematic review tables/charts Journal Article |
| Publicado: |
Lippincott Williams & Wilkins
Aug2022
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=158076392&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 158076392 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 15277941 38T jtl: Advances in Skin & Wound Care issn: 15277941 maglogo: N pubinfo: dt: Aug2022 vid: 35 iid: 8 pid: 5086 pub: Lippincott Williams & Wilkins place: Baltimore, Maryland artinfo: ui: 158076392 158076392 158076392 10.1097/01.ASW.0000820252.96869.8e 158076392 ppf: 454 ppct: 7 formats: tig: atl: Onset of Pyoderma Gangrenosum in Patients on Biologic Therapies: A Systematic Review. aug: au: Lytvyn, Yuliya Mufti, Asfandyar Maliyar, Khalad Sachdeva, Muskaan Yeung, Jensen affil: At the University of Toronto, Ontario, Canada, Yuliya Lytvyn, PhD is Medical Student, Temerty Faculty of Medicine sug: subj: Inflammation Drug Therapy Biological Therapy Adverse Effects Pyoderma Gangrenosum Risk Factors Risk Assessment Human Systematic Review Medline Embase Rituximab Tumor Necrosis Factor Immunoglobulins Administration and Dosage Administration, Intravenous Adrenal Cortex Hormones Administration and Dosage Administration, Oral Antibiotics Administration and Dosage Interleukins Cyclosporine Male Female Canada Ontario Male Female ab: OBJECTIVE: To summarize clinical outcomes of paradoxical pyoderma gangrenosum (PG) onset in patients on biologic therapy. METHODS: The authors conducted MEDLINE and EMBASE searches using PRISMA guidelines to include 57 patients (23 reports). RESULTS: Of the included patients, 71.9% (n = 41/57) noted PG onset after initiating rituximab, 21.1% (n = 12/57) noted tumor necrosis factor α (TNF-α) inhibitors, 5.3% (n = 3/57) reported interleukin 17A inhibitors, and 1.8% (n = 1/57) reported cytotoxic T-lymphocyte-associated protein 4 antibodies. The majority of patients (94.3%) discontinued biologic use. The most common medications used to resolve rituximab-associated PG were intravenous immunoglobulins, oral corticosteroids, and antibiotics, with an average resolution time of 3.3 months. Complete resolution of PG in TNF-α-associated cases occurred within an average of 2.2 months after switching to another TNF-α inhibitor (n = 1), an interleukin 12/23 inhibitor (n = 2), or treatment with systemic corticosteroids and cyclosporine (n = 3), systemic corticosteroids alone (n = 1), or cyclosporine alone (n = 1). CONCLUSIONS: Further investigations are warranted to determine whether PG onset is associated with underlying comorbidities, the use of biologic agents, or a synergistic effect. Nevertheless, PG may develop in patients on rituximab or TNF-α inhibitors, suggesting the need to monitor and treat such adverse effects. pubtype: Academic Journal doctype: research systematic review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|